A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3836-3845

  Shah, Manish A ^a   Kortmansky, Jeremy ^a   Motwani, Monica ^a   Drobnjak, Marija ^a   Gonen, Mithat ^a   Yi, Sandy ^a   Weyerbacher, Amanda ^a   Cordon Cardo, Carlos ^a   Lefkowitz, Robert ^a   Brenner, Baruch ^a   O'Reilly, Eileen ^a   Saltz, Leonard ^a   Tong, William ^a   Kelsen, David P ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BILIRUBIN; FLAVOPIRIDOL; IRINOTECAN; PROTEIN P21;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; GERM CELL TUMOR; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STOMACH CARCINOMA; TUMOR BIOPSY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIRUBIN; CAMPTOTHECIN; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLAVONOIDS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PIPERIDINES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21044432331     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2651     Document Type: Article

References (45)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
2. Harper J, Elledge SJ. Cdk inhibitors in develpment and cancer. Curr Opin Genet Dev 1996;6:56-64.
3. Chen Y-N, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999;96:4325-9.
4. Senderowicz AM. Cyclin-dependent kinases as targets for cancer therapy. In: Giaccone G, Schilsky R, Sondel P, editors. Cancer Chemotherapy and Biological Response Modifiers, Annual 20. Elsevier Science; 2002. p. 169-88.
5. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-95.
6. 1 arrest with inhibition of cyclin-dependent kinase CDC2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
7. Losiewicz MD, Carlson BA, Kaus G, Sausville EA, Wosland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994:201;589-95.
8. Dumant JA. HMR Report No. B/98/0189/R, B/98/0188/R, 8/98/0187/R. HMR Oncology; 1996.
9. Rapella A, Negrioli A, Melillo G, et al. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. J Cancer 2002;99:658-64.
10. Wall NR, O'Connor DS, Plescia J, et al. Suppression of survivn phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-5.
11. Takada Y, Aggarwal BB. Flavopiridol inhibits Nf-kB activation induced by various carcinogens and inflammatory agents through inhibition of IkBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004;279:4750-9.
12. Thomas AL, O'Byrne K, Steward WP. Chemotherapy for upper gastrointestinal tumours. Postgrad Med J 2000;76:321-7.
13. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000;18:371-5.
14. Shapiro GI, Patterson A, Lynch C, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590-9.
15. Schwartz GK, Ilson D, Saltz L, O'Reilly E, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985-92.
16. Lin L-S, Hecht JR. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 2000;19:1130a.
17. Burdette-Radoux S, Tozer RG, Lohmann R, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004;22:315-22.
18. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14:1270-3.
19. Motwani M, Rizzo C, Sirotnak FM, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003;2:549-55.
20. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83.
21. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT-116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7:4209-19.
22. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002;62:1707-17.
23. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-36.
24. Shah MA, Schwartz GK. Cell Cycle mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-81.
25. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002;62:3950-5.
26. Schwartz GK, O'Reilly E, Ilson D. et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
27. De Bruijn P, Verwiej J, Loos WJ, et al. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr 1997;698:277-85.
28. Shah MA, Kemeny N, Hummer A, et al. Drg1 expression in 131 colorectal liver metastases: correlation with clinical parameters and patient outcomes. Clin Cancer Res. In press 2005.
29. Gibladi M, Perrier D. Pharmacokinetics. 2nd ed. Dekker; 1982.
30. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
31. Hagenauer B, Salamon A, Thalhammer T, et al. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 2001;29:407-14.
32. McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol 2004;22:1356-9.
33. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-72.
34. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56:4856-61.
35. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasm. J Clin Oncol 2002;20:4074-82.
36. Zhai S, Sausville EA, Senderowicz AM, et al. Clinical pharmacology and pharmacogenetics of flavopiridol 1-hr i.v. infusion in patients with refractory neoplasms. Anticancer Drugs 2003;14:125-35.
37. Dai R, Zhai S, Wei X, et al. Inhibition of human cytochrome p450 1A2 by flavones: a molecular modeling study. J Protein Chem 1998;17:643-50.
38. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
39. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
40. Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004;22:1439-46.
41. Ramirez J, Iyer L, Journault K, et al. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 2002;19:588-94.
42. Rau B, Sturm I, Lage H, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;22:3391-401.
43. Guan RJ, Ford HL, Fu Y, et al. Drg-1 as a differenatiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000;60:749-55.
44. Bandyopadhyay S, Pai SK, Hirota S, et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 2004;23:5675-81.
45. Bandyopadhyay S, Pai SK, Gross SC, et al. The Drg1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003;63:1731-6.